News Quantified

XGN – exagen inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics, Upcoming Webinar Hosted by Xtalks

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform [Yahoo! Finance]

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. (NASDAQ: XGN) had its "outperform" rating re-affirmed by analysts at William Blair.

-4.1%

BEAT

18.8%

BEAT

-6.3%

BEAT

1.7%

BEAT

Form 4 EXAGEN INC. For: Nov 15 Filed by: Black Jeffrey G.

Form 4 EXAGEN INC. For: Nov 14 Filed by: ABALLI JOHN

Form 8-K EXAGEN INC. For: Nov 12

Form 10-Q EXAGEN INC. For: Sep 30

Form 144 EXAGEN INC. Filed by: Adawi Kamal

Top News Gainers

3/25 Form 10-K EXAGEN INC. For: Dec 31 37.4%

12/20 Do Hedge Funds Love Exagen Inc. (XGN)? [Yahoo! Finance News] 23.8%

1/27 Form SC 13G EXAGEN INC. Filed by: RTW INVESTMENTS, LP 13.5%

9/18 Form S-1MEF EXAGEN INC. 10.6%

3/27 Form 4 EXAGEN INC. For: Mar 11 Filed by: PALLARES EBETUEL 10.0%

4/18 Exagen Inc. (NYSE: XGN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 6.5%

12/16 Is Affimed NV (AFMD) Going to Burn These Hedge Funds? [Yahoo! Finance News] 4.7%

10/21 Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America 3.9%

9/20 Form 424B4 EXAGEN INC. 2.6%

11/22 Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management 2.4%

Top News Decliners

2/18 Exagen to Present at Cowen and Company 40th Annual Healthcare Conference -28.0%

3/16 Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease -27.7%

3/26 Form 3 EXAGEN INC. For: Mar 24 Filed by: Zack Debra -24.8%

3/11 Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020 -13.3%

3/24 Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer -9.3%

2/7 Form SC 13G EXAGEN INC. Filed by: Hunt Holdings Limited Partnership -8.2%

11/21 Exagen Inc. Announces $26.2 Million Debt Refinancing -6.8%

4/29 Form DEF 14A EXAGEN INC. For: Apr 29 -6.6%

3/3 Exagen Inc. (NYSE: XGN) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock. -6.3%

12/20 Exagen Inc. (NYSE: XGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day